BR112012031580A2 - derivado de tetra-hidrocarbolina - Google Patents
derivado de tetra-hidrocarbolinaInfo
- Publication number
- BR112012031580A2 BR112012031580A2 BR112012031580A BR112012031580A BR112012031580A2 BR 112012031580 A2 BR112012031580 A2 BR 112012031580A2 BR 112012031580 A BR112012031580 A BR 112012031580A BR 112012031580 A BR112012031580 A BR 112012031580A BR 112012031580 A2 BR112012031580 A2 BR 112012031580A2
- Authority
- BR
- Brazil
- Prior art keywords
- drug
- enpp2
- inhibitory activity
- present
- excretion disorder
- Prior art date
Links
- 229940079593 drug Drugs 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000029142 excretion Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000036325 urinary excretion Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
derivado de tetra-hidrocarbolina. um objetivo da presente invenção é fornecer um fármaco tendo a atividade inibitória de enpp2 que é um alvo diferente daquele entre o fármaco existente, como um medicamento útil em um paciente com transtorno de excreção uirinária para quem o fármaco existente tem o efeito insuficiente. a presente invenção fornece um composto represntado pela fórmula geral (i): em que a definição de cada grupo é definida na descrição tendo a atividade inibitória de enpp2, um sal do mesmo ou um solvato do mesmo ou um pró-fármaco do mesmo, e um agente para prevenir ou tratar o transtorno de excreção urinária e/ou melhorar os sintomas do mesmo, contendo o mesmo como um ingrediente ativo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010154280 | 2010-07-06 | ||
JP2011060765 | 2011-03-18 | ||
PCT/JP2011/065312 WO2012005227A1 (ja) | 2010-07-06 | 2011-07-05 | テトラヒドロカルボリン誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012031580A2 true BR112012031580A2 (pt) | 2016-11-08 |
Family
ID=45441206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012031580A BR112012031580A2 (pt) | 2010-07-06 | 2011-07-05 | derivado de tetra-hidrocarbolina |
Country Status (21)
Country | Link |
---|---|
US (3) | US9006246B2 (pt) |
EP (2) | EP2592081B1 (pt) |
JP (2) | JP5821848B2 (pt) |
KR (1) | KR101831005B1 (pt) |
CN (1) | CN102971318B (pt) |
AU (1) | AU2011274970C1 (pt) |
BR (1) | BR112012031580A2 (pt) |
CA (1) | CA2802216C (pt) |
DK (1) | DK2592081T3 (pt) |
ES (2) | ES2693247T3 (pt) |
IL (1) | IL223028A0 (pt) |
MX (1) | MX2012015279A (pt) |
MY (1) | MY161001A (pt) |
NZ (1) | NZ603575A (pt) |
PL (1) | PL2592081T3 (pt) |
PT (1) | PT2592081T (pt) |
RU (1) | RU2572818C2 (pt) |
SG (1) | SG186826A1 (pt) |
TW (2) | TWI586666B (pt) |
WO (1) | WO2012005227A1 (pt) |
ZA (1) | ZA201300032B (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2592081B1 (en) | 2010-07-06 | 2017-03-08 | Ono Pharmaceutical Co., Ltd. | Tetrahydrocarboline derivative |
ES2587856T3 (es) * | 2011-03-18 | 2016-10-27 | Ono Pharmaceutical Co., Ltd. | Derivado de tetrahidrocarbolina |
WO2015002755A2 (en) * | 2013-06-21 | 2015-01-08 | The Broad Institute, Inc. | Compounds for the treatment of malaria |
WO2015163435A1 (ja) | 2014-04-24 | 2015-10-29 | 田辺三菱製薬株式会社 | 新規2-アミノ-ピリジン及び2-アミノ-ピリミジン誘導体及びその医薬用途 |
TW201613917A (en) | 2014-06-06 | 2016-04-16 | Biogen Ma Inc | ATX modulating agents |
GB201501870D0 (en) | 2015-02-04 | 2015-03-18 | Cancer Rec Tech Ltd | Autotaxin inhibitors |
GB201502020D0 (en) | 2015-02-06 | 2015-03-25 | Cancer Rec Tech Ltd | Autotaxin inhibitory compounds |
US10118904B2 (en) | 2015-06-05 | 2018-11-06 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of Demyelinating Diseases |
WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
CN110483424A (zh) * | 2018-06-11 | 2019-11-22 | 上海睿升化工科技有限公司 | 一种1-h-1,2,3-三氮唑-4-羧酸叔丁酯的制备方法 |
BR112020027051A2 (pt) | 2018-07-27 | 2021-03-30 | Mitsubishi Tanabe Pharma Corporation | Derivados de piridina 3,5-dissubstituída e piridazina 3,5-dissubstituída e uso farmacêutico dos mesmos |
US10947253B2 (en) | 2019-08-05 | 2021-03-16 | Ankh Life Sciences Limited | Fused polycyclic dimers |
CN111272918A (zh) * | 2020-03-31 | 2020-06-12 | 广西-东盟食品检验检测中心 | 一种那非类医药中间体的高效液相色谱-质谱检测方法 |
CN111454260B (zh) * | 2020-05-25 | 2023-02-28 | 贵州大学 | 一类含异丙醇胺亚结构的1,2,3,4-四氢-β-咔啉类化合物及其制备方法和应用 |
WO2024053650A1 (ja) * | 2022-09-06 | 2024-03-14 | 小野薬品工業株式会社 | ジアシルグリセロールキナーゼαおよび/またはζ阻害活性を有する化合物およびその医薬用途 |
CN115728428A (zh) * | 2022-11-15 | 2023-03-03 | 山东省医药工业设计院有限公司 | 一种他达拉非中间体顺式四氢咔啉盐酸盐有关物质的测定方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL130238A0 (en) * | 1999-06-01 | 2000-06-01 | Peptor Ltd | Conformationally constrained backbone cyclized interleukin-6 antagonists |
UA74826C2 (en) | 2000-05-17 | 2006-02-15 | Ortho Mcneil Pharm Inc | ?-carboline derivatives as phosphodiesterase inhibitors |
WO2002000657A2 (en) | 2000-06-26 | 2002-01-03 | Lilly Icos Llc | Condensed pyrazindione derivatives |
AU2002249890A1 (en) * | 2001-02-12 | 2002-08-28 | Lilly Icos Llc | Carboline derivatives |
EP1533294A4 (en) | 2002-05-28 | 2007-07-04 | Ono Pharmaceutical Co | BETA-ALANINE DERIVATIVE AND USE THEREOF |
US7872133B2 (en) | 2003-06-23 | 2011-01-18 | Ono Pharmaceutical Co., Ltd. | Tricyclic heterocycle compound |
CA2554150A1 (en) | 2004-01-23 | 2005-08-04 | Chiron Corporation | Tetrahydrocarboline compounds as anticancer agents |
BRPI0509660A (pt) | 2004-04-09 | 2007-10-09 | Millennium Pharm Inc | compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias |
ES2459742T3 (es) * | 2004-12-22 | 2014-05-12 | Ono Pharmaceutical Co., Ltd. | Compuesto tricíclico y uso del mismo |
JP2008297278A (ja) | 2007-06-01 | 2008-12-11 | Astellas Pharma Inc | Lpa受容体アゴニスト |
EP2592081B1 (en) | 2010-07-06 | 2017-03-08 | Ono Pharmaceutical Co., Ltd. | Tetrahydrocarboline derivative |
ES2587856T3 (es) | 2011-03-18 | 2016-10-27 | Ono Pharmaceutical Co., Ltd. | Derivado de tetrahidrocarbolina |
-
2011
- 2011-07-05 EP EP11803561.7A patent/EP2592081B1/en not_active Not-in-force
- 2011-07-05 WO PCT/JP2011/065312 patent/WO2012005227A1/ja active Application Filing
- 2011-07-05 PT PT118035617T patent/PT2592081T/pt unknown
- 2011-07-05 SG SG2012095501A patent/SG186826A1/en unknown
- 2011-07-05 EP EP15190651.8A patent/EP3002285B1/en not_active Not-in-force
- 2011-07-05 KR KR1020137000248A patent/KR101831005B1/ko active IP Right Grant
- 2011-07-05 DK DK11803561.7T patent/DK2592081T3/en active
- 2011-07-05 JP JP2012523864A patent/JP5821848B2/ja not_active Expired - Fee Related
- 2011-07-05 AU AU2011274970A patent/AU2011274970C1/en not_active Ceased
- 2011-07-05 BR BR112012031580A patent/BR112012031580A2/pt not_active Application Discontinuation
- 2011-07-05 ES ES15190651.8T patent/ES2693247T3/es active Active
- 2011-07-05 PL PL11803561T patent/PL2592081T3/pl unknown
- 2011-07-05 MX MX2012015279A patent/MX2012015279A/es active IP Right Grant
- 2011-07-05 TW TW104140762A patent/TWI586666B/zh not_active IP Right Cessation
- 2011-07-05 CN CN201180033552.7A patent/CN102971318B/zh not_active Expired - Fee Related
- 2011-07-05 ES ES11803561.7T patent/ES2623286T3/es active Active
- 2011-07-05 CA CA2802216A patent/CA2802216C/en not_active Expired - Fee Related
- 2011-07-05 TW TW100123652A patent/TWI525092B/zh not_active IP Right Cessation
- 2011-07-05 NZ NZ603575A patent/NZ603575A/en not_active IP Right Cessation
- 2011-07-05 RU RU2013104866/04A patent/RU2572818C2/ru not_active IP Right Cessation
- 2011-07-05 MY MYPI2012701218A patent/MY161001A/en unknown
- 2011-07-05 US US13/807,947 patent/US9006246B2/en not_active Expired - Fee Related
-
2012
- 2012-11-14 IL IL223028A patent/IL223028A0/en active IP Right Grant
-
2013
- 2013-01-02 ZA ZA2013/00032A patent/ZA201300032B/en unknown
-
2015
- 2015-02-25 US US14/630,708 patent/US9636330B2/en not_active Expired - Fee Related
- 2015-05-18 JP JP2015100802A patent/JP6065052B2/ja not_active Expired - Fee Related
-
2017
- 2017-03-21 US US15/464,408 patent/US9974777B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012031580A2 (pt) | derivado de tetra-hidrocarbolina | |
BR112016013299A2 (pt) | Composto | |
BR112018000906A2 (pt) | ?composto, medicamento, métodos de inibição da histona desacetilase em um mamífero, e para a profilaxia ou o tratamento de doenças, e, uso de um composto? | |
BR112014007257A2 (pt) | composto, medicamento, métodos para inibir um colesterol 24-hidrolase em um mamífero e para a profilaxia ou tratamento de doença neurodegenerativa em um mamífero, e, uso do composto ou sal | |
BR112015020650A2 (pt) | inibidores de histona demetilases | |
BR112015024530A2 (pt) | composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto | |
BR112015020302A2 (pt) | derivado de pirazol | |
BR112014025711A2 (pt) | composto, medicamento, e, uso de um composto | |
BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
BR112015009168A2 (pt) | composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4 | |
BR112012025390B8 (pt) | Composto de tetraidrobenzotiofeno ou sal do mesmo e seu uso no tratamento ou prevenção de hiperfosfatemia, bem como composição farmacêutica compreendendo o dito composto | |
BR112014029851A2 (pt) | composto, inibidores da atividade da enzima ros1 quinase e da enzima ntrk quinase, composição farmacêutica, agente antitumor, agente terapêutico para um tumor, método para tratamento de um tumor, e, agente para tratamento de um tumor | |
BR112016002465A2 (pt) | terapia da combinação para o tratamento de câncer | |
BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
BR112015001419A2 (pt) | composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios | |
BR112019016291A2 (pt) | novo composto heterocíclico, seu método de preparação e composição farmacêutica compreendendo o mesmo | |
BR112012021364A2 (pt) | "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas". | |
BR112015003729A2 (pt) | composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente | |
BR112013002250A2 (pt) | composto, medicamento, método para a profilaxia ou tratamento de depressão, esquisofrenia, mal de alzheimer ou distúrbio de hiperatividade e déficit de atenção, e, uso de um composto. | |
BR112015029353A2 (pt) | derivados de pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
BR112016017317A8 (pt) | composto, antagonista de trpa1, medicamento, e, método para profilaxia e/ou tratamento de uma doença que envolve trpa1 | |
BR112015022650A2 (pt) | inibidores de cinase induzível por sal macrocíclico | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |